Acadia Pharmaceuticals, Inc. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Acadia Pharmaceuticals with three other
companies in this sector in the United States:
FibroGen Inc
(2018
sales of $212.96 million
of which 100%
was Biopharmaceutical Preparations),
Eagle Pharmaceuticals, Inc
($213.31 million
of which 100%
was Pharmaceuticals), and
Amarin Corporation PLC
($229.21 million
of which 100%
was Research&Development).
Sales Analysis.
Acadia Pharmaceuticals reported sales of $223.81 million
for the
year ending
December of 2018.
This
represents
an
increase of 79.2%
versus 2017, when the company's sales were $124.90 million.
This was the third consecutive year of growth at Acadia Pharmaceuticals.